Abstract
The new EU Regulation on health technology assessment (htar) provides for joint clinical assessments (jca) of health technologies at EU level. When Member States carry out health technology assessments (hta) at the national level, they shall give due consideration to the results of a jca and comply with other obligations of the Regulation. This article aims to clarify what these obligations mean for the Member States and whether jca results have to be considered outside a national health technology assessment as well. In this context, the question of which processes qualify as 'national hta' and which requirements need to be fulfilled to trigger the obligations under Article 13 htar are discussed in more detail in this paper.
| Original language | English |
|---|---|
| Pages (from-to) | 171-186 |
| Number of pages | 16 |
| Journal | European Journal of Health Law |
| Volume | 31 |
| Issue number | 2 |
| Early online date | 13 Mar 2024 |
| DOIs | |
| Publication status | Published - 2024 |
Austrian Fields of Science 2012
- 505010 Medical law
Keywords
- health technology assessment
- hta
- htar
- jca
- joint clinical assessment
- national healthcare decision-making
- soft law